Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 61,290 |
|
|||||
| News | - | ||||||
| Day High | 3.8861 | Low High |
|||||
| Day Low | 3.36 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Notable Labs Ltd | NTBL | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.0799 | -2.11% | 3.71 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.80 | 3.36 | 3.8861 | 3.71 | 3.7899 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 459 | 61,290 | $ 3.69 | $ 226,341 | - | 2.25 - 5.27 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:56:01 | 2 | $ 3.43 | USD |
Notable Labs Ltd Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 33.39M | 9.00M | - | 658k | -32.3M | -3.59 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Notable Labs News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NTBL Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.72 | 4.24 | 3.36 | 3.92 | 32,801 | -0.01 | -0.27% |
| 1 Month | 2.69 | 4.24 | 2.65 | 3.49 | 28,655 | 1.02 | 37.92% |
| 3 Months | 4.50 | 5.27 | 2.25 | 3.74 | 57,628 | -0.79 | -17.56% |
| 6 Months | 4.50 | 5.27 | 2.25 | 3.74 | 57,628 | -0.79 | -17.56% |
| 1 Year | 4.50 | 5.27 | 2.25 | 3.74 | 57,628 | -0.79 | -17.56% |
| 3 Years | 4.50 | 5.27 | 2.25 | 3.74 | 57,628 | -0.79 | -17.56% |
| 5 Years | 4.50 | 5.27 | 2.25 | 3.74 | 57,628 | -0.79 | -17.56% |
Notable Labs Description
| Vascular Biogenics Ltd is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of first-in-class treatments for cancer. The lead product candidate of the company is VB-111 which is a gene-based biologic which is being developed for solid tumor indications for recurrent glioblastoma, an aggressive form of brain cancer. The company is also engaged in conducting a program targeting anti-inflammatory diseases, based on the use of Lecinoxoid platform technology. The product brands of the company include VTS, Vascular Targeting Systems, Vbl, Vascular Biogenics And Vascular Therapeutics. |
